| scholarly article | Q13442814 |
| P50 | author | Richard Smith | Q89491339 |
| Merit E Cudkowicz | Q95746107 | ||
| P2093 | author name string | Hong Yu | |
| David Schoenfeld | |||
| Eric A Macklin | |||
| Kathleen Myers | |||
| Erik Pioro | |||
| Gary Pattee | |||
| James Wymer | |||
| Gregg Meekins | |||
| Kimberly Goslin | |||
| Michael Sirdofsky | |||
| P2860 | cites work | Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) | Q24201081 |
| Pathological laughter and crying: a link to the cerebellum | Q28214416 | ||
| Dextromethorphan Plus Ultra Low‐Dose Quinidine Reduces Pseudobulbar Affect | Q28293218 | ||
| Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration | Q28513873 | ||
| Predicting Speech Intelligibility Decline in Amyotrophic Lateral Sclerosis Based on the Deterioration of Individual Speech Subsystems. | Q30383800 | ||
| Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect | Q30634431 | ||
| Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system | Q30859681 | ||
| Symptomatic treatment of respiratory and nutritional failure in amyotrophic lateral sclerosis | Q33932519 | ||
| Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial | Q34361996 | ||
| Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial | Q34436090 | ||
| Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options | Q34815254 | ||
| Electrical impedance myography in the evaluation of the tongue musculature in amyotrophic lateral sclerosis. | Q35842997 | ||
| An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions | Q36551001 | ||
| Dextromethorphan/quinidine: a novel dextromethorphan product for the treatment of emotional lability | Q36675422 | ||
| The pharmacology of sigma-1 receptors | Q37445561 | ||
| Dysarthria in amyotrophic lateral sclerosis: A review | Q37698625 | ||
| Dextromethorphan/quinidine: in pseudobulbar affect | Q37863094 | ||
| Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect | Q38270903 | ||
| Symptomatic care of patients with amyotrophic lateral sclerosis | Q39351303 | ||
| Tongue thickness evaluation using ultrasonography can predict swallowing function in amyotrophic lateral sclerosis patients. | Q40590205 | ||
| An autoradiographic study of dextromethorphan high-affinity binding sites in rat brain: sodium-dependency and colocalization with paroxetine | Q41843239 | ||
| Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease | Q42540896 | ||
| Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers | Q45040972 | ||
| Bipap improves survival and rate of pulmonary function decline in patients with ALS. | Q48758870 | ||
| Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. | Q50940024 | ||
| Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. | Q51580604 | ||
| Prognosis in amyotrophic lateral sclerosis: a population-based study. | Q51950008 | ||
| The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). | Q53535985 | ||
| The interaction between neuroactive steroids and the σ1 receptor function: behavioral consequences and therapeutic opportunities | Q55922778 | ||
| Dextromethorphan and Quinidine for Treating Agitation in Patients With Alzheimer Disease Dementia | Q57914499 | ||
| Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis | Q58250570 | ||
| A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group | Q72759362 | ||
| Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group | Q74093661 | ||
| Use of fiberoptic endoscopic evaluation of swallowing (FEES) in patients with amyotrophic lateral sclerosis | Q80598004 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P2507 | corrigendum / erratum | Erratum to: Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial | Q42333585 |
| P433 | issue | 3 | |
| P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
| P304 | page(s) | 762-772 | |
| P577 | publication date | 2017-07-01 | |
| P1433 | published in | Neurotherapeutics | Q15716631 |
| P1476 | title | Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial | |
| P478 | volume | 14 |
| Q56531747 | Amyotrophic lateral sclerosis |
| Q55664870 | Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale). |
| Q38646588 | Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies. |
| Q64228443 | Clinical Measures of Bulbar Dysfunction in ALS |
| Q59796297 | GM604 regulates developmental neurogenesis pathways and the expression of genes associated with amyotrophic lateral sclerosis |
| Q104503062 | Improving clinical trial outcomes in amyotrophic lateral sclerosis |
| Q50055247 | Incorporating upper motor neuron health in ALS drug discovery |
| Q58096837 | Minimally Detectable Change and Minimal Clinically Important Difference of a Decline in Sentence Intelligibility and Speaking Rate for Individuals With Amyotrophic Lateral Sclerosis |
| Q89584199 | Novel therapeutic targets for amyotrophic lateral sclerosis |
| Q90075812 | Reliability and validity of speech & pause measures during passage reading in ALS |
| Q74441418 | Research round-up |
| Q64086441 | Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials |
| Q64075393 | Tracking a Fast-Moving Disease: Longitudinal Markers, Monitoring, and Clinical Trial Endpoints in ALS |
| Q42333585 | Erratum to: Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial | main subject | P921 |
Search more.